Abstract
Gastrointestinal (GI) dysfunction is a common but underestimated feature in Parkinson's
disease (PD). Out of the multimodal spectrum of treatment options, there currently
are only a few pharmacological treatments available to improve gastrointestinal motility
and symptoms. Because enteric nervous function is mainly regulated by transmitters
different from those involved in the brain, dopamine replacement is not a treatment
option in PD patients. This article focuses on the known regulative mechanism of GI
function and presents known and upcoming treatment options for GI dysfunction in PD.
Abbreviations:
5-HT (5-hydroxytryptamine), CNS (central nervous system), DA (dopamine), ENS (enteric nervous system), GI (gastrointestinal), LB (Lewy bodies), MPTP (1-methyl-4-phenyl-1:2:3:6-tetrahydropyridine), PD (Parkinson's disease), TH (tyrosine hydroxylase), VIP (vasoactive intestinal polypeptide), PNS (peripheral nervous system), MSA (multi system atrophy Hr-QoL, health-related quality of life)Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of the Neurological SciencesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages).J Neurol. Oct. 2002; 249 (III/1–5)
- Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology.Neurology. Apr. 1992; 42: 726-732
- Gastrointestinal dysfunction in Parkinson's disease.Semin Neurol. Sep. 1996; 16: 245-250
- Gastrointestinal dysfunction in Parkinson's disease.Lancet Neurol. Feb. 2003; 2: 107-116
- Neural control of the gastrointestinal tract: implications for Parkinson disease.Mov Disord. Jun 15 2008; 23: 1065-1075
- Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen.J Neural Transm. May 2003; 110: 517-536
- Lewy bodies in the enteric nervous system in Parkinson's disease.Arch Histol Cytol. 1989; 52: 191-194
- Autonomic nervous system screening in patients with early Parkinson's disease.in: IEarly diagnosis and preventive therapy in Parkinson's disease. Springer, Wien, New York1989: 41-48
- Frequency of bowel movements and the future risk of Parkinson's disease.Neurology. Aug. 14 2001; 57: 456-462
- Bowel movement frequency in late-life and incidental Lewy bodies.Mov Disord. Aug. 15 2007; 22: 1581-1586
- Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses.Acta Neuropathol. 1988; 76: 217-221
- Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology.Neurosci Lett. Mar. 20 2006; 396: 67-72
- Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease.Exp Neurol. Sep. 2007; 207: 4-12
- MPTP-induced parkinsonism extends to a subclass of TH-positive neurons in the gut.Brain Res. Oct. 8 2010; 1355: 195-206
- Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models?.Trends Pharmacol Sci. Sep. 2009; 30: 475-483
- Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology.Neurobiol Dis. Oct. 2009; 36: 96-102
- Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's disease.Exp Neurol. Jul. 2009; 218: 154-161
- The role of MPTP in Parkinson's disease: connecting brain and gut?.Exp Neurol. Apr. 2008; 210: 281-285
- Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes.Hum Mol Genet. May 1 2010; 19: 1633-1650
- Treatment of patients with diabetic gastroparesis.Gastroenterol Hepatol (N Y). Jun 2010; 6: 1-16
- Motor control of the stomach.Eur Rev Med Pharmacol Sci. Aug. 2008; 12: 41-51
- Parkinson's disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system.Acta Neuropathol. 1990; 79: 581-583
- Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation.Lancet. Sep. 30 1995; 346: 861-864
- Mechanosensitive afferent fibers in the gastrointestinal and lower urinary tracts.Prog Pain Res Manag. 1995; 5 (516): 75-98
- Sensory neurone responses to mucosal noxae in the upper gut: relevance to mucosal integrity and gastrointestinal pain.Neurogastroenterol Motil. Oct. 2002; 14: 459-475
- Signalling the state of the digestive tract.Auton Neurosci. Apr. 30 2006; 125: 76-80
- The neurobiology of stress and gastrointestinal disease.Gut. Dec. 2000; 47: 861-869
- Controller–regulator model of the central nervous system.J Integr Neurosci. Dec. 2002; 1: 129-143
- Stress and the gastrointestinal tract III. Stress-related alterations of gut motor function: role of brain corticotropin-releasing factor receptors.Am J Physiol Gastrointest Liver Physiol. Feb. 2001; 280: G173-G177
- What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them?.Mov Disord. Nov. 15 2010; 25: 2493-2500
- Gastroparesis and functional dyspepsia: excerpts from the AGA/ANMS meeting.Neurogastroenterol Motil. Feb. 2010; 22: 113-133
- Rome III: New standard for functional gastrointestinal disorders.J Gastrointestin Liver Dis. Sep. 2006; 15: 237-241
- American Gastroenterological Association medical position statement: diagnosis and treatment of gastroparesis.Gastroenterology. Nov. 2004; 127: 1589-1591
- Predictors of gastric emptying in Parkinson's disease.Neurogastroenterol Motil. May 2006; 18: 369-375
- Impaired gastric myoelectrical activity in patients with Parkinson's disease and effect of levodopa treatment.Dig Dis Sci. May 2004; 49: 744-749
- Gastric myoelectrical differences between Parkinson's disease and multiple system atrophy.Mov Disord. Aug. 15 2009; 24: 1579-1586
- Dyssynergic defecation and biofeedback therapy.Gastroenterol Clin North Am. Sep. 2008; 37 (viii): 569-586
- Functional bowel disorders.Gastroenterology. Apr. 2006; 130: 1480-1491
- The evolution and origin of motor complications in Parkinson's disease.Neurology. 2000; 55 (discussion S1–3): S13-S20
- Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients.Clin Neuropharmacol. Mar–Apr. 2006; 29: 61-67
- Prokinetics and fundic relaxants in upper functional GI disorders.Curr Opin Pharmacol. Dec. 2008; 8: 690-696
- The effect of exercise on the gastrointestinal tract.Sports Med. Mar. 1990; 9: 159-172
- Effect of heavy exercise on gastrointestinal transit in endurance athletes.Scand J Gastroenterol. Jun 2011; 46: 673-677
- Exercise improves efficacy of levodopa in patients with Parkinson's disease.Mov Disord. Feb. 15 2007; 22: 427-430
- Nutrition concerns for the patient with gastroparesis.Curr Gastroenterol Rep. Aug. 2007; 9: 295-302
- Delayed gastric emptying: whom to test, how to test, and what to do.Curr Treat Options Gastroenterol. Jul. 2006; 9: 295-304
- Effect of carbonated water on gastric emptying and intragastric meal distribution.Dig Dis Sci. Jan. 1997; 42: 34-39
- Gastric electric stimulation for the treatment of gastroparesis.Curr Gastroenterol Rep. Aug. 2007; 9: 286-294
- Predictive factors for clinical improvement with Enterra gastric electric stimulation treatment for refractory gastroparesis.Dig Dis Sci. Aug. 2008; 53: 2072-2078
- Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology.Neurology. Mar. 16 2010; 74: 924-931
- Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease.Clin Neuropharmacol. Oct. 1992; 15: 375-380
- Patient characteristics and treatment outcome in functional anorectal pain.Dis Colon Rectum. Jul. 2011; 54: 870-875
- The role of biofeedback therapy in functional proctologic disorders.Scand J Surg. 2004; 93: 184-190
- Domperidone improves myogenically transmitted antroduodenal coordination by blocking dopaminergic receptor sites.Scand J Gastroenterol Suppl. 1984; 96: 101-110
- Metoclopramide-induced movement disorders. Clinical findings with a review of the literature.Arch Intern Med. Nov. 1989; 149: 2486-2492
- Drug Insight: from disturbed motility to disordered movement—a review of the clinical benefits and medicolegal risks of metoclopramide.Nat Clin Pract Gastroenterol Hepatol. Mar. 2006; 3: 138-148
- Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease.Mov Disord. Nov. 1997; 12: 952-957
- Effect of domperidone on the motility of antrum, pylorus and duodenum in man.Scand J Gastroenterol Suppl. 1981; 67: 195-198
- Domperidone: review of pharmacology and clinical applications in gastroenterology.Am J Gastroenterol. Sep. 2007; 102: 2036-2045
- Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects.Dig Dis Sci. Jan. 2011; 56: 115-124
- Motilin and ghrelin as prokinetic drug targets.Pharmacol Ther. Aug. 2009; 123: 207-223
- Efficacy of mitemcinal, a motilin agonist, on gastrointestinal symptoms in patients with symptoms suggesting diabetic gastropathy: a randomized, multi-center, placebo-controlled trial.Aliment Pharmacol Ther. Jul. 1 2007; 26: 107-116
- Modulation of gastric motor activity by a centrally acting stimulus, circular vection, in humans.Am J Physiol Gastrointest Liver Physiol. May 2001; 280: G850-G857
- Motilin effects on the proximal stomach in patients with functional dyspepsia and healthy volunteers.Am J Physiol Gastrointest Liver Physiol. May 2003; 284: G776-G781
- Postprandial ghrelin response is reduced in patients with Parkinson's disease and idiopathic REM sleep behaviour disorder: a peripheral biomarker for early Parkinson's disease?.J Neurol. Jun 2011; 258: 982-990
- Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial.Gut. Sep. 2001; 49: 395-401
- GM-611 (Chugai Pharmaceutical).Curr Opin Investig Drugs. Apr. 2001; 2: 555-557
- Motilides: a long and winding road: lessons from mitemcinal (GM-611) on diabetic gastroparesis.Regul Pept. Jun 5 2009; 155: 18-23
- Effects of oral mitemcinal (GM-611), erythromycin, EM-574 and cisapride on gastric emptying in conscious rhesus monkeys.Dig Dis Sci. Apr. 2008; 53: 912-918
- Advantages of azithromycin over erythromycin in improving the gastric emptying half-time in adult patients with gastroparesis.J Neurogastroenterol Motil. Oct. 2010; 16: 407-413
- Effect of atilmotin on gastrointestinal transit in healthy subjects: a randomized, placebo-controlled study.Neurogastroenterol Motil. Jan. 2006; 18: 28-36
- Actions and therapeutic pathways of ghrelin for gastrointestinal disorders.Nat Rev Gastroenterol Hepatol. Jun 2009; 6: 343-352
- Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study.Gut. Dec. 2005; 54: 1693-1698
- Ghrelin gastrokinetic action in patients with neurogenic gastroparesis.Peptides. Jul. 2006; 27: 1603-1606
- Effect of cisapride on response fluctuations in Parkinson's disease.Mov Disord. Jan. 1995; 10: 81-84
- Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson's disease.Parkinsonism Relat Disord. Dec. 2005; 11: 499-502
- Gastrointestinal motility problems in patients with Parkinson's disease. Effects of antiparkinsonian treatment and guidelines for management.Drugs Aging. Apr. 1997; 10: 249-258
- Aggravation of parkinsonian tremor by cisapride.Clin Neuropharmacol. Feb. 1995; 18: 76-78
- Prokinetic agents and QT prolongation: a familiar scene with new actors.Curr Drug Saf. Jan. 2010; 5: 73-78
- Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease.Mov Disord. Jan. 2006; 21: 115-116
- Tegaserod and the risk of cardiovascular ischemic events: an observational cohort study.J Cardiovasc Pharmacol Ther. Jun 2010; 15: 151-157
- Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder.Gastroenterology. Feb. 2001; 120: 354-360
- Role of intestinal chemoreception in the induction of gastrointestinal sensations.Dtsch Tierarztl Wochenschr. Dec. 1998; 105: 441-444
- Endogenous cholecystokinin in postprandial lower esophageal sphincter function and fundic tone in humans.Am J Physiol. Dec. 1998; 275: G1266-G1273
- Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo.Aliment Pharmacol Ther. Jun 1996; 10: 411-419
- CCK1 receptor antagonist, dexloxiglumide: effects on human isolated gallbladder. Potential clinical applications.Minerva Gastroenterol Dietol. Sep. 2003; 49: 211-216
- New and emerging treatments for irritable bowel syndrome and functional dyspepsia.Expert Opin Emerg Drugs. May 2002; 7: 91-98
- Pharmacokinetic profile of dexloxiglumide.Clin Pharmacokinet. 2006; 45: 1177-1188
- Progress with novel pharmacological strategies for gastro-oesophageal reflux disease.Drugs. 2004; 64: 347-361
- The effects on diet, anastomotic type, and loxiglumide on gastric emptying following gastrojejunostomy.Int J Surg. Apr. 2009; 7: 163-167
- CCK in anxiety and cognitive processes.Neurosci Biobehav Rev. Oct. 1998; 22: 815-825
- Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study.Mov Disord. Jul. 15 2007; 22: 1239-1244
- Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients.Mov Disord. Jun 2005; 20: 680-686
- Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A.Am J Gastroenterol. Jun 2003; 98: 1439-1440
- Inhibitory effect of dopamine on canine gastric fundus.Naunyn Schmiedebergs Arch Pharmacol. May 1984; 326: 22-28
- A placebo-controlled trial of prucalopride for severe chronic constipation.N Engl J Med. May 29 2008; 358: 2344-2354
- The effects of tegaserod on oesophageal function and bolus transport in healthy volunteers: studies using concurrent high-resolution manometry and videofluoroscopy.Aliment Pharmacol Ther. Oct. 1 2006; 24: 1017-1027
- 5-HT4 receptor agonists: similar but not the same.Neurogastroenterol Motil. 2008 Feb. 2008; 20: 99-112
- Clinical trial: effects of tegaserod on gastric motor and sensory function in patients with functional dyspepsia.Aliment Pharmacol Ther. Nov. 15 2007; 26: 1399-1407
- Role of cholecystokinin in the regulation of liquid gastric emptying and gastric motility in humans: studies with the CCK antagonist loxiglumide.Gut. Oct. 1997; 41: 500-504
- Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia.Gut. Mar. 2001; 48: 347-355
Article info
Publication history
Published online: July 29, 2011
Accepted:
June 27,
2011
Received in revised form:
June 15,
2011
Received:
March 15,
2011
Identification
Copyright
© 2011 Elsevier B.V. Published by Elsevier Inc. All rights reserved.
